<p>Malignant Diseases:</p>

<p>Cyclophosphamide is indicated for the treatment of:</p>

<ul>
	<li>Malignant&nbsp;lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin&#39;s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma,&nbsp;Burkitt&#39;s lymphoma</li>
	<li>Multiple myeloma</li>
	<li>Leukemias: chronic lymphocytic&nbsp;leukemia,&nbsp;chronic granulocytic leukemia&nbsp;(it is usually ineffective in acute blastic crisis), acute&nbsp;myelogenousand monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during&nbsp;remission&nbsp;is effective in prolonging its duration)</li>
	<li>Mycosis fungoides&nbsp;(advanced disease)</li>
	<li>Neuroblastoma&nbsp;(disseminated disease)</li>
	<li>Adenocarcinoma&nbsp;of the ovary</li>
	<li>Retinoblastoma</li>
	<li>Carcinoma&nbsp;of the breast</li>
</ul>

<p>Cyclophosphamide, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other&nbsp;antineoplastic&nbsp;drugs.</p>

<p>Minimal Change Nephrotic Syndrome in Pediatric Patients:</p>

<p>Cyclophosphamide is indicated for the treatment of biopsy proven minimal change nephrotic syndrome in pediatrics patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy.</p>